AstraZeneca Gets Regulatory Approval for Ondexxya in Japan
29 März 2022 - 8:45AM
Dow Jones News
By Kyle Morris
AstraZeneca PLC said Tuesday that Ondexxya has been approved in
Japan for the reversal of acute major bleeds in patients treated
with Factor Xa inhibitors apixaban, rivaroxaban or edoxaban.
The pharmaceutical major said that a Phase 3 trial showed that
Ondexxya rapidly and markedly reversed anti-FXa activity in
patients with acute major bleeding.
Ondexxya is a recombinant protein designed to bind to Factor Xa
inhibitors and reverse the anticoagulant effect when needed due to
life-threatening or uncontrolled bleeding.
Write to Kyle Morris at kyle.morris@dowjones.com
(END) Dow Jones Newswires
March 29, 2022 02:30 ET (06:30 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
